Eiger BioPharmaceuticals, Inc. (EIGR) Social Stream

Eiger BioPharmaceuticals, Inc. (EIGR): $6.24

0.14 (+2.30%)

POWR Rating

Component Grades













Add EIGR to Watchlist
Sign Up

Industry: Biotech


of 396

in industry

Eiger BioPharmaceuticals Inc (EIGR) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Eiger BioPharmaceuticals Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 4 $49 $21 $31.25 $8.52 266.78%
2022-03-11 4 $28 $21 $25.333 $8.52 197.34%
2022-03-18 3 $29 $22 $26 $8.52 205.16%

The Trend in the Analyst Price Target

Over the past 49 weeks, EIGR's average price target has gone down $5.67.

EIGR reports an average of 318.56% for its upside potential over the past 49 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-12 6 49 22 31.670 8.26 283.41%
2021-06-28 6 49 23 32.330 8.94 261.63%
2022-03-11 3 28 21 25.333 5.10 396.73%
2022-03-11 4 28 21 25.333 5.10 396.73%
2022-03-18 3 29 22 26.000 7.92 228.28%

EIGR Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 3 0 0 0 0 3

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for EIGR as an investment opportunity.

  • EIGR has a greater upside potential (average analyst target price relative to current price) than 357.82% of all US stocks.
  • In the context of all US stocks, Eiger BioPharmaceuticals Inc's number of analysts covering the stock is greater than 60.44% of them.
  • In the context of Pharmaceutical Products stocks, Eiger BioPharmaceuticals Inc's variance in analysts' estimates is lower than -35.58% of them.
  • In terms of how Eiger BioPharmaceuticals Inc fares relative to stocks in the small market cap category, note that its average analyst price target is higher than 248.43% of that group.

In the Pharmaceutical Products industry, DTIL, DNAC, and DBVT are the three stocks most similar to Eiger BioPharmaceuticals Inc regarding the price target and analyst recommendation information presented here.

Is EIGR a Buy, Hold or Sell? See the POWR Ratings now!

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4454 seconds.